Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

13 evidence topics · 15 sources

Summary

In a US claims analysis of 3,409 individuals with CIDP, 2,758 (81%) were treated during the first year, and steroids (73% of those treated) followed by immunoglobulin (65%) were the most commonly used treatments. Neurology specialists are the most frequent prescribers of immunoglobulin, which may be given in a hospital clinic, physician's office, infusion clinic, or at home; the Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) prefilled syringe may be administered subcutaneously by patients or caregivers after proper instruction, and the vial is to be administered by a healthcare professional only.

The company positions claseprubart as a potential first-line biologic given as a subcutaneous, infrequently dosed, self-administered injection, and CAPTIVATE enrolls standard-of-care-refractory, standard-of-care-treated, and standard-of-care-naive patients without requiring immunoglobulin withdrawal. Other complement inhibitors are in development: Sanofi announced that the phase 3 MOBILIZE trial of riliprubart, an antibody that selectively inhibits activated C1s, in CIDP refractory to standard-of-care treatment will be stopped after an independent data monitoring committee determined at an interim analysis that it is unlikely to provide sufficient efficacy, and that continuation of VITALIZE will be evaluated accordingly; argenx is advancing two phase 3 trials of empasiprubart, an antibody targeting C2, one of them a head-to-head comparison with intravenous immunoglobulin.

Company positioning of claseprubart in CIDP